PROFESSOR DAVID KERR, UNIVERSITY OF OXFORD, ENGLAND (CHAIR)
Professor David Kerr, CBE. is a Professor of Cancer Medicine at the University of Oxford, England. He focuses on innovative approaches to cancer treatment, including novel biomarkers and inhibitors of key chemical pathways, and his research has contributed to saving thousands of lives over the past 20 years.
He has made significant contributions to reforming the UK’s National Health Service as a Founding Commissioner for Health Improvement, and developed a 20-year plan for the future of the NHS in Scotland, known as the ‘Kerr Report’. He has also established INDOX and AfrOx to improve quality of cancer care in India and Sub Saharan Africa, and has served as Health Advisor to two British Prime Ministers.
Professor Kerr has been distinguished with the first Nye Bevan award for Innovation by the NHS (2000), elected Fellow of the Academy of Medical Sciences (2000), honorary Fellow of the Royal College of General Practitioners (2007), the ESMO award for distinguished contribution to cancer therapy and research (2006) and appointed a Commander of the Order of the British Empire by HM the Queen (2002).
Professor Kerr was the Chief Research Advisor and Member of the Supreme Council of Health in Qatar (2009-10), and the ESMO President (2010-12). His patents have launched biotech spinout companies such as Cobra Therapeutics, Celleron and Oxford Cancer Biomarkers.
To date, he has secured over £60 million worth of scientific funding and grants, and co-authored over 400 articles in peer-reviewed journals such as the New England Journal of Medicine, The Lancet and Nature Genetics. He was Editor-in-Chief for Annals of Oncology between 2001-08, and Founding Editor in Chief of the Journal of Global Oncology, 2015-17.
PROFESSOR DIRK ARNOLD, ASKLEPIOS KLINIK ALTONA
Professor Dirk Arnold, MD. is the Chief Physician for Haematology and Internal Oncology, Asklepios Klinik Altona. He was formerly the Director of Instituto CUF de Oncologia, a Comprehensive Cancer Centre in Lisbon and Porto in Portugal, and a Professor of Internal Medicine at the University of Hamburg in Germany.
As a leading international specialist in medical oncology, he focuses on the treatment of GI and genitourinary cancers using molecular targeted therapies, immunotherapy, multi-model treatment strategies and has a particular interest in early drug developments. He is further interested in research network structures, methodologies of clinical research, benefit evaluation procedures and palliative care.
Professor Arnold is the Section Editor for Gastrointestinal Cancers of the ESMO Guidelines Committee and Chairman of the German AIO Colorectal Cancer Study Group, a major collaborative group in clinical oncology. Within this framework, he served as the founding member of the Central Clinical Trials Office. He is also a member of the Task Force Colorectal Cancer, Board Member of the Gastrointestinal Cancer Study Group of EORTC, and a member of the scientific advisory board of some pharmaceutical companies.
Professor Arnold has co-authored over 150 peer-reviewed articles and several book chapters, is an Associate Editor for GI Cancers of the ESMO Open scientific journal, and a reviewer for the Journal of Clinical Oncology, Annals of Oncology, The Lancet and The Lancet Oncology.
He is an active member of ESMO, the American Society of Clinical Oncology (ASCO) the German Cancer Society, and the German Society of Haematology and Medical Oncology (DGHO).
PROFESSOR JEAN-YVES BLAY, CENTRE LÉON BÉRARD, FRANCE
Professor Jean-Yves Blay, MD. is the Director of the European Reference Network on Adult Cancers – ERN EURACAN (Solid Tumours), Director General of the Centre Léon Bérard, the comprehensive cancer centre of Lyon and the Rhône-Alpes region, and an oncologist, researcher and medical oncologist professor at the University Claude Bernard, France. He focuses on sarcomata, targeted treatment of cancer, the biology of the breast carcinoma, and the relationship between tumour immunologic microenvironment and malignant cells, with the goal of clinical applications in the field of diagnosis, prognosis and treatment.
He has been distinguished with the Hamilton-Fairly award from ESMO (2012) and the Henry and Mary-Jane Mitjaville prize from the National Academy of Medicine (2013).
Professor Blay is the Subject Editor for Sarcoma and Gastrointestinal Stromal Tumors for the ESMO Guidelines Committee, and the Director of ERN-EURACAN, designated by the EU Commission in 2016 to improve the quality of care for patients with rare cancers in the European Union.
He is also the President of the French Sarcoma Group, the Network Leader of NETSARC sarcoma treatment reference centres, and a member of the ESMO EU Policy Committee and the ESMO Principles of Clinical Trials and Systematic Therapy Faculty. Previously, he served as the President of EORTC between 2009 and 2012 and the former Principal Investigator of Conticanet, an EU Commission network of research excellence. He is also a member of the scientific advisory board for Invivis Pharmaceutics Inc, Deciphera Pharmaceuticals LLC and Transgene SA.
Professor Blay has co-authored over 550 peer-reviewed articles and book chapters, advises various national and international institutions and research organisations, and is an active member of several oncological organisations and societies, such as ESMO, ASCO and AACR. He has been a member of the ESMO Open journal’s editorial board since 2016, and a reviewer for the Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology and the European Journal of Cancer.
PROFESSOR ALFREDO CARRATO, INSTITUTION RAMON Y CAJAL UNIVERSITY HOSPITAL, SPAIN
Professor Alfredo Carrato, MD. PhD, is the Director of Medical Oncology and the Institute of Health Research at the Ramon y Cajal University Hospital, and Professor of Medical Oncology at Alcala University, Spain. He has a translational approach to research and has been involved with molecular epidemiology and biology of solid tumours, such as pancreatic and urothelial cancers.
He is the co-ordinator of the Pancreatic Cancer Overall Survival Registry (PancreOS), a multi-stakeholder platform aiming to bring together experts from across Europe to improve care for patients with pancreatic cancer. He has also been a member of the Executive Committee of the Spanish Co-operative Group for the Treatment of Digestive Tumours (TTD) since 1992.
Professor Carrato has previously served as the President of the National Advisory Commission on Medical Oncology at the Spanish Ministries of Health and Education (2003-2013) and the President for both the Spanish Society of Cancer Research (ASEICA), and the Spanish Federation of Oncologic Societies (FESEO) (2013-2015).
Professor Carrato has co-authored over 250 peer-reviewed articles, 80 chapters in medical books and is an active member of several oncological societies such as ESMO, ASCO and EACR.
PROFESSOR CHRISTIAN BUSKE, UNIVERSITY OF ULM, GERMANY
Professor Christian Buske, MD. is Medical Director at the Comprehensive Cancer Centre and the Institute of Experimental Cancer Research at the University of Ulm, and an attending Physician and Professor of Medicine at the University Hospital Ulm, Germany. His research focuses on indolent B-cell non-Hodgkin lymphoma – in particular, follicular lymphoma and Waldenström’s Macroglobulinemia – of which he is the Principal Investigator of a number of national and international clinical trials.
He is the Subject Editor for Haematological Malignancies of the ESMO Guidelines Committee, a member of the ESMO Haematological Malignancy Faculty Group, co-ordinates the European Consortium for Waldenström’s Macroglobulinemia (ECWM) and President Elect of the German Lymphoma Alliance (GLA). In addition, he is heading a large translational research group focusing on the biology of haematological neoplasms.
Professor Buske has co-authored over 150 peer-reviewed articles and is an active member of several oncological societies such as ASH, ESMO, DGHO and the International Society for Haematology and Stem Cells (IZEH). He serves on the editorial board of Leukemia and has reviewed among others for the New England Journal of Medicine, Science, Cancer Cell, Cell Stem Cell, The Journal of Clinical Oncology and Blood.
PROFESSOR WINALD GERRITSEN MD PHD, RADBOUD UNIVERSITY MEDICAL CENTRE, NETHERLANDS
Winald Gerritsen is a professor of Tumour Immunotherapy at Radboud University Medical Centre Nijmegen. Professor Gerritsen also serves as an Adjunct Professor at John Hopkins University, and is a member of the Royal Holland Society of Sciences and Humanities.
Professor Gerritsen has previously served as the Chairman of the Commission on Clinical Research (Dutch Cancer Society) and the Commission on Biotherapy (National Translational Cancer Research Network). Professor Gerritsen is a member of the scientific advisory board for Aglaia Biomedical Ventures and ORCA therapeutics.
Professor Gerritsen has particular experience in translational research, with a special interest in tumour-immunology and prostate cancer. He has been involved in several clinical studies involving adenoviral, adeno-associated viral and retroviral gene therapies.
PROFESSOR MARC PEETERS, UNIVERSITY OF ANTWERP, BELGIUM
Marc Peeters is Head of the Oncology Department at Antwerp University Hospital and the Multidisciplinary Oncology Centre (MOCA). He is also Digestive Oncology Co-ordinator of the oncology care programme at University Hospital Ghent (UZ Gent), and Chairman of the Belgian Centre for Oncology.
Professor Peeters’ research focuses on the identification of molecular markers and therapeutics modulations in tumours of the digestive system. He is keen to expand oncology based on a strong multidisciplinary approach.